The TruSight RNA Pan-Cancer panel provides a comprehensive analysis of the cancer transcriptome. It offers:
- Gene expression information, variant calling, and fusion detection with known and novel gene fusion partners
- Optimized, low-input protocol for a wide range of sample types including FFPE
- A comprehensive view of cancer pathways
- Economical RNA sequencing (RNA-Seq) on a desktop sequencer
Highly Sensitive and Economical Targeted Sequencing
The TruSight RNA Pan-Cancer panel enables the quantitative measurement of gene expression as well as the detection of gene fusions with both known and novel gene fusion partners. The panel accommodates as little as 10 ng of total RNA input (or 20 ng from FFPE samples). The focus on a subset of relevant genes enables RNA-Seq with high sensitivity on a benchtop sequencer, allowing cost-effective access to NGS for any lab.
Intuitive Cloud-based Data Analysis
Analysis can be performed using the BaseSpace RNA-Seq Alignment App. This intuitive tool performs fusion calling and variant detection, and provides gene expression profiles, offering a comprehensive solution to cancer researchers.
TruSight RNA Pan-Cancer Sample Datasets
Note that access to this data requires a login.
Register for BaseSpace Sequence Hub
10 ng of human reference RNA (UHR), human reference brain RNA (Brain), cell line RNA (MCF7), and 20 ng of breast tumor FFPE RNA (BT) were prepared using the TruSight RNA Pan-Cancer Panel and sequenced on the MiSeq System. Read mapping and fusion calling were performed using the RNA-Seq Alignment App with STAR aligner on BaseSpace Sequence Hub.
Human reference RNA (HBRR and UHRR), cell line RNA (MCF7), and breast tumor RNA samples were prepared using the TruSight RNA Pan-Cancer panel, and 8 samples were sequenced on the MiniSeq System at a 2x76bp read length with single indexing. The total yield was 4.2 Gb with 96.8% of bases at or above Q30.
Browse the data in BaseSpace Sequence Hub: